Vaxcyte Shares Surge As Its Pneumococcal Vaccine On Par With Pfizer's Shot In Study

• Vaxcyte Inc (NASDAQ: PCVX) announced positive topline results from the Phase 1/2 proof-of-concept study evaluating VAX-24, the company's investigational 24-valent pneumococcal conjugate vaccine (PCV), in healthy adults aged 18-64.

• VAX-24 met the primary safety and tolerability objectives, demonstrating a safety profile similar to Pfizer Inc's (NYSE: PFE) Prevnar 20 (PCV20) for all doses studied.

• In the study, VAX-24 met or exceeded the established regulatory immunogenicity standards for all 24 serotypes at the conventional 2.2mcg dose, which the company intends to move forward into a Phase 3 program.

• At this dose, VAX-24 met the standard opsonophagocytic activity (OPA) response non-inferiority criteria for all 20 serotypes common with PCV20, of which 16 achieved higher immune responses.

• Additionally, at all three doses, VAX-24 met the standard superiority criteria for all four serotypes unique to VAX-24. These four incremental serotypes cover 10-15 percent of strains causing invasive pneumococcal disease (IPD) over the current standard of care in adults.

• VAX-24 demonstrated a safety and tolerability profile similar to PCV20 at all doses studied.

• The full six-month safety follow-up is ongoing for the Phase 2 portion of the study. Final results are anticipated in 1H of 2023.

• Price Action: PCVX shares are up 71% at $35.18 on the last check Monday.

 

See more from Benzinga

• Alpine Immune Sciences Stops Davoceticept Trials In Cancer Indications After Second Patient Death

• Medtronic To Spin Off Its Combined Patient Monitoring & Respiratory Interventions Businesses

• If You Invested $100 When Elon Musk First Tweeted About Dogecoin, Here's How Much You'd Have Now - Tesla

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.